Daily Monitoring of Serum Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein Is Useful for Predicting Therapeutic Effect of Tolvaptan in Cirrhotic Ascites

被引:0
作者
Takamura, Masaaki [1 ]
Sakamaki, Akira [1 ]
Arao, Yoshihisa [1 ]
Setsu, Toru [1 ]
Kamimura, Hiroteru [1 ]
Yokoo, Takeshi [1 ]
Kamimura, Kenya [1 ]
Tsuchiya, Atsunori [1 ]
Terai, Shuji [1 ]
机构
[1] Niigata Univ, Div Gastroenterol & Hepatol, Grad Sch Med & Dent Sci, Niigata, Niigata, Japan
关键词
hepatic ascites; liver cirrhosis; tolvaptan; treatment efficacy; Wisteria floribunda agglutinin-positive Mac-2 binding protein; MAC-2-BINDING PROTEIN; LIVER-CIRRHOSIS; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; FIBROSIS; SODIUM; LECTIN;
D O I
10.1620/tjem.252.287
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Wisteria floribunda agglutinin (WFA) is a lectin that binds to the sugar chain of Mac-2 binding protein (M2BP), and WFA-positive M2BP (WFA(+)-M2BP) has been reported as a useful marker for assessing liver fibrosis in chronic liver disease. Tolvaptan (TLV), a selective vasopressin V2 receptor antagonist, is used for cirrhotic ascites in Japan, but good predictors of treatment efficacy remain to be established. Our aim was to investigate whether WFA(+)-M2BP monitoring before and after TLV administration can predict treatment efficacy in patients with cirrhotic ascites. Twenty patients (10 men), with a median age of 72 years, were enrolled. Cirrhosis was caused by hepatitis B virus (n = 3), hepatitis C virus (n = 4), alcohol (n = 8), and others (n = 5). Responders were defined as having a body weight loss of >= 1.5 kg/week after TLV administration. Serum WFA(+)-M2BP levels were measured at baseline and days 1, 3, and 7 after TLV treatment. Twelve patients (60%) were responders. Baseline WFA(+)-M2BP levels were correlated with serum albumin levels (r = -0.544, P = 0.013). The baseline furosemide dose was lower and platelet count was higher in responders than in non-responders (P < 0.05). The ratio of WFA(+)-M2BP levels on day 1 after TLV administration to baseline was lower in responders than in non-responders (P < 0.05). The decrease in the ratio discriminated responders from non-responders (AUC = 0.844, P < 0.05). In conclusion, monitoring serum WFA(+)-M2BP is helpful for predicting the efficacy of TLV treatment in patients with cirrhotic ascites.
引用
收藏
页码:287 / 296
页数:10
相关论文
共 29 条
  • [1] Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease
    Abe, Masanori
    Miyake, Teruki
    Kuno, Atsushi
    Imai, Yasuharu
    Sawai, Yoshiyuki
    Hino, Keisuke
    Hara, Yuichi
    Hige, Shuhei
    Sakamoto, Michiie
    Yamada, Gotaro
    Kage, Masayoshi
    Korenaga, Masaaki
    Hiasa, Yoichi
    Mizokami, Masashi
    Narimatsu, Hisashi
    [J]. JOURNAL OF GASTROENTEROLOGY, 2015, 50 (07) : 776 - 784
  • [2] Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema
    Atsukawa, Masanori
    Tsubota, Akihito
    Takaguchi, Koichi
    Toyoda, Hidenori
    Iwasa, Motoh
    Ikegami, Tadashi
    Chuma, Makoto
    Nozaki, Akito
    Uojima, Haruki
    Hiraoka, Atsushi
    Fukunishi, Shinya
    Yokohama, Keisuke
    Tada, Toshifumi
    Kato, Keizo
    Abe, Hiroshi
    Tani, Joji
    Okubo, Hironao
    Watanabe, Tsunamasa
    Hattori, Nobuhiro
    Tsutsui, Akemi
    Senoh, Tomonori
    Yoshida, Yuji
    Okubo, Tomomi
    Itokawa, Norio
    Nakagawa-Iwashita, Ai
    Kondo, Chisa
    Arai, Taeang
    Michitaka, Kojiro
    Iio, Etsuko
    Kumada, Takashi
    Tanaka, Yasushito
    Takei, Yoshiyuki
    Iwakiri, Katsuhiko
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (07) : 1229 - 1237
  • [3] Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema
    Atsukawa, Masanori
    Tsubota, Akihito
    Kato, Keizo
    Abe, Hiroshi
    Shimada, Noritomo
    Asano, Toru
    Ikegami, Tadashi
    Koeda, Mai
    Okubo, Tomomi
    Arai, Taeang
    Nakagawa-Iwashita, Ai
    Yoshida, Yuji
    Hayama, Korenobu
    Itokawa, Norio
    Kondo, Chisa
    Chuganji, Yoshimichi
    Matsuzaki, Yasushi
    Iwakiri, Katsuhiko
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (06) : 1256 - 1263
  • [4] Hepatic stellate cells secreting WFA+-M2BP: Its role in biological interactions with Kupffer cells
    Bekki, Yuki
    Yoshizumi, Tomoharu
    Shimoda, Shinji
    Itoh, Shinji
    Harimoto, Norifumi
    Ikegami, Toru
    Kuno, Atsushi
    Narimatsu, Hisashi
    Shirabe, Ken
    Maehara, Yoshihiko
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (07) : 1387 - 1393
  • [5] BERNARDI M, 1985, Z KARDIOL, V74, P129
  • [6] Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
    Costello-Boerrigter, LC
    Smith, WB
    Boerrigter, G
    Ouyang, J
    Zimmer, CA
    Orlandi, C
    Burnett, JC
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2006, 290 (02) : F273 - F278
  • [7] COMPENSATED CIRRHOSIS - NATURAL-HISTORY AND PROGNOSTIC FACTORS
    GINES, P
    QUINTERO, E
    ARROYO, V
    TERES, J
    BRUGUERA, M
    RIMOLA, A
    CABALLERIA, J
    RODES, J
    ROZMAN, C
    [J]. HEPATOLOGY, 1987, 7 (01) : 122 - 128
  • [8] Haga Yuki, 2016, Diseases, V4, DOI 10.3390/diseases4040038
  • [9] Response criteria of tolvaptan for the treatment of hepatic edema
    Hiramine, Yasunari
    Uojima, Haruki
    Nakanishi, Hiroyuki
    Hiramatsu, Akira
    Iwamoto, Takuya
    Kimura, Mutsuumi
    Kawaratani, Hideto
    Terai, Shuji
    Yoshiji, Hitoshi
    Uto, Hirofumi
    Sakaida, Isao
    Izumi, Namiki
    Okita, Kiwamu
    Koike, Kazuhiko
    [J]. JOURNAL OF GASTROENTEROLOGY, 2018, 53 (02) : 258 - 268
  • [10] Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema
    Hiramine, Yasunari
    Uto, Hirofumi
    Imamura, Yasushi
    Hiwaki, Takuya
    Kure, Takeshi
    Ijuin, Sho
    Oda, Kohei
    Mawatari, Seiichi
    Kumagai, Kotaro
    Tokunaga, Koki
    Higashi, Hirofumi
    Kanetsuki, Ichiro
    Kubozono, Osamu
    Maenohara, Shigeho
    Ido, Akio
    [J]. HEPATOLOGY RESEARCH, 2017, 47 (06) : 542 - 557